Cytek Biosciences, Inc. CTKB NASDAQ

Cytek Biosciences, Inc. (CTKB) generated $-771K in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $1M, free cash flow was $-1.77M.

Free cash flow margin was -2.9% of revenue. Cash conversion ratio was 0.02x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (49/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (10/100) — Cash conversion ratio was 0.02x suggests some earnings are non-cash items

Overall SharesGrow Score: 50/100 with 2/7 criteria passed.